Reaktionsgleichung
[CH:1]1([C:4]2[N:9]=[C:8]([C:10]([NH:12][C:13]3[CH:17]=[N:16][N:15]([CH3:18])[C:14]=3[C:19]([OH:21])=O)=[O:11])[C:7]([NH:22][C:23]3[CH:24]=[N:25][CH:26]=[N:27][CH:28]=3)=[N:6][CH:5]=2)[CH2:3][CH2:2]1.Cl.[C:30]([O:34][C:35]([N:37]1[CH2:41][CH2:40][CH:39]([NH2:42])[CH2:38]1)=[O:36])([CH3:33])([CH3:32])[CH3:31]>>[C:30]([O:34][C:35]([N:37]1[CH2:41][CH2:40][CH:39]([NH:42][C:19]([C:14]2[N:15]([CH3:18])[N:16]=[CH:17][C:13]=2[NH:12][C:10]([C:8]2[C:7]([NH:22][C:23]3[CH:28]=[N:27][CH:26]=[N:25][CH:24]=3)=[N:6][CH:5]=[C:4]([CH:1]3[CH2:3][CH2:2]3)[N:9]=2)=[O:11])=[O:21])[CH2:38]1)=[O:36])([CH3:33])([CH3:31])[CH3:32]Komponenten
3
Edukt 2
Produkt 1
Versuchsvorschrift
The product was obtained starting from 4-{[6-cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carbonyl]-amino}-2-methyl-2H-pyrazole-3-carboxylic acid (30 mg, 79 μmol) and tert-butyl-3-aminopyrrolidine-1-carboxylate hydrochloride (23 mg, 103 μmol) according to the method described in example 64, step 6 after purification by preparative HPLC using an acetonitrile/water gradient as yellow solid (28 mg, 65%).
Aufarbeitung
- customThe product was obtained
- customafter purification by preparative HPLC
Quellen und Nachweise
- ORD-Eintrag
- ord-8abcc7dce585483aa55fde80158eeb22
- Quelldatensatz
- uspto-grants-2014_01
- Patentnummer
- US08623866B2
Verknüpfte Notizen
Wird geladen…